Sildenafil [Revatio]: FDA Clarifies Warning About Pediatric Use for Pulmonary Arterial Hypertension (PAH)
March 31, 2014 – The American Food and Drug Administration (FDA) is clarifying its previous recommendation related to prescribing Sidenafil [Revatio] for children with pulmonary arterial hypertension (PAH). Note that the pharmacologically active compound sildenafil is also the pharmacologically active …